mRNA

News

Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.

News

Strong phase 3 results for Moderna's individualised skin cancer vaccine could pave the way for a leap forward in the field.

News

After a series of regulatory twists and turns, the FDA has approved Moderna's mRNA-based influenza vaccine mFlusiva.

News

Moderna has started first-in-human testing of its mRNA vaccine against Bundibugyo Ebola virus, as the outbreak in DRC gathers pace.

News

Moderna saw its Q1 sales nearly triple to $389m, almost a threefold rise on the same period of 2025, with international markets driving the increase.

Event

Partner Content

Advancing mRNA's Therapeutic Potential to Combat All Diseases